MoneyWorks4Me

Lupin enters into licensing agreement with Alvion

05 Apr 2022 Evaluate

Lupin has entered into a licensing agreement with Alvion Pharmaceuticals P.C. (Alvion) to commercialize medicines for Cardiometabolic diseases in the Southeast Asia region.

The company is committed to providing new affordable treatment options to healthcare providers and patients. By commercializing cardiometabolic drugs in the Southeast Asian region, the company will play a significant role in improving the quality of healthcare and access to medicines.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..